Efficacy of vonoprazan for the prevention of bleeding after gastric endoscopic submucosal dissection with continuous use of antiplatelet agents

Abstract

Background Post-procedural bleeding, after gastric endoscopic submucosal dissection (ESD) for high risk thromboembolic cases that require continuous antiplatelet therapy, is challenging. Its incidence rate is > 20 % among those using conventional antacids. We evaluated the efficacy of perioperative management with vonoprazan to prevent post-ESD bleeding.

Materials and methods This was a multicenter prospective interventional trial conducted at 10 Japanese referral centers. Patients who regularly used antiplatelet agents (aspirin or thienopyridine derivatives, etc.) and who required continuous antithrombotic medication due to high thromboembolic risk were enrolled. They underwent gastric ESD with continuous aspirin therapy. Oral administration of vonoprazan (20 mg daily) was started from the day of ESD and continued for 28 days. The primary end point was the incidence of post-ESD bleeding. The sample size was 50 patients, and vonoprazan was considered to be effective when the upper threshold of the 95 % confidence interval (CI) for post-ESD bleeding did not exceed 20 %.

Results Although 50 patients were enrolled, one patient withdrew consent. Therefore, 49 patients were included in the analysis. One patient who used aspirin and clopidogrel experienced bleeding 11 days after ESD. The overall post-ESD bleeding rate was 2.0 % (1/49; 95 %CI 0.4–10.7 %). Thromboembolic events were not observed. One case of ESD-associated adverse events (perforation) and one case of drug-associated adverse events (drug eruption, possibly due to vonoprazan) were observed.

Conclusions Vonoprazan may be efficacious for preventing post-ESD bleeding in patients using continuous antiplatelet therapy, warranting further comparative study to definitively test the effectiveness of the drug.

• References

• 1 Akasaka T, Nishida T, Tsutsui S. et al. Short-term outcomes of endoscopic submucosal dissection (ESD) for early gastric neoplasm: multicenter survey by Osaka University ESD study group. Dig Endosc 2011; 23: 73-77
• 2 Kato M, Nishida T, Hamasaki T. et al. Outcomes of ESD for patients with early gastric cancer and comorbid liver cirrhosis: a propensity score analysis. Surg Endosc 2015; 29: 1560-1566
• 3 Yoshioka T, Nishida T, Tsujii M. et al. Renal dysfunction is an independent risk factor for bleeding after gastric ESD. Endosc Int Open 2015; 3: E39-E45
• 4 Nishida T, Kato M, Yoshio T. et al. Endoscopic submucosal dissection in early gastric cancer in elderly patients and comorbid conditions. World J Gastrointest Endosc 2015; 7: 524-531
• 5 Fujimoto K, Fujishiro M, Kato M. et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc 2014; 26: 1-14
• 6 Ono S, Fujishiro M, Yoshida N. et al. Thienopyridine derivatives as risk factors for bleeding following high risk endoscopic treatments: Safe Treatment on Antiplatelets (STRAP) study. Endoscopy 2015; 47: 632-637
• 7 Cho SJ, Choi IJ, Kim CG. et al. Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms. Endoscopy 2012; 44: 114-121
• 8 Tounou S, Morita Y. Gastric and duodenal endoscopic submucosal dissection in patients on aspirin therapy has increased risk of hemorrhage but is feasible. Gastroenterol Endosc 2011; 53: 3326-3335
• 9 Takizawa K, Oda I, Gotoda T. et al. Routine coagulation of visible vessels may prevent delayed bleeding after endoscopic submucosal dissection--an analysis of risk factors. Endoscopy 2008; 40: 179-183
• 10 Okada K, Yamamoto Y, Kasuga A. et al. Risk factors for delayed bleeding after endoscopic submucosal dissection for gastric neoplasm. Surg Endosc 2011; 25: 98-107
• 11 Suzuki H, Takizawa K, Hirasawa T. et al. Short-term outcomes of multicenter prospective cohort study of gastric endoscopic resection: ‘Real-world evidence’ in Japan. Dig Endosc 2019; 31: 30-39
• 12 Uedo N, Takeuchi Y, Yamada T. et al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol 2007; 102: 1610-1616
• 13 Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr Opin Gastroenterol 2010; 26: 367-378
• 14 Li XQ, Andersson TB, Ahlstrom M. et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-827
• 15 Katsuki H, Nakamura C, Arimori K. et al. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 1997; 52: 391-396
• 16 Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet 1999; 37 (Suppl. 02) 53-59
• 17 Malhotra K, Katsanos AH, Bilal M. et al. Cerebrovascular outcomes with proton pump inhibitors and thienopyridines: A systematic review and meta-analysis. Stroke 2018; 49: 312-318
• 18 Ho PM, Maddox TM, Wang L. et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944
• 19 Sakurai Y, Mori Y, Okamoto H. et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects – a randomised open-label cross-over study. Aliment Pharmacol Ther 2015; 42: 719-730
• 20 Jenkins H, Sakurai Y, Nishimura A. et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015; 41: 636-648
• 21 Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: Pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2016; 55: 409-418
• 22 Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017; 20: 1-19
• 23 Maekawa S, Nomura R, Murase T. et al. Complete closure of artificial gastric ulcer after endoscopic submucosal dissection by combined use of a single over-the-scope clip and through-the-scope clips (with videos). Surg Endosc 2015; 29: 500-504
• 24 Tsuji Y, Fujishiro M, Kodashima S. et al. Polyglycolic acid sheets and fibrin glue decrease the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms (with video). Gastrointest Endosc 2015; 81: 906-912
• 25 Tounou S, Morita Y, Hosono T. Continuous aspirin use does not increase post-endoscopic dissection bleeding risk for gastric neoplasms in patients on antiplatelet therapy. Endosc Int Open 2015; 3: E31-E38
• 26 Lim JH, Kim SG, Kim JW. et al. Do antiplatelets increase the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms?. Gastrointest Endosc 2012; 75: 719-727
• 27 Sanomura Y, Oka S, Tanaka S. et al. Continued use of low-dose aspirin does not increase the risk of bleeding during or after endoscopic submucosal dissection for early gastric cancer. Gastric Cancer 2014; 17: 489-496
• 28 Kataoka Y, Tsuji Y, Hirasawa K. et al. Endoscopic tissue shielding to prevent bleeding after endoscopic submucosal dissection: a prospective multicenter randomized controlled trial. Endoscopy 2019; 51: 619-627
• 29 Green Jr. FW, Kaplan MM, Curtis LE. et al. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74: 38-43
• 30 Kagawa T, Iwamuro M, Ishikawa S. et al. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. Aliment Pharmacol Ther 2016; 44: 583-591
• 31 Hamada K, Uedo N, Tonai Y. et al. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: A prospective randomized phase II study. J Gastroenterol 2019; 54: 122-130
• 32 Horikawa Y, Mizutamari H, Mimori N. et al. Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis. Scand J Gastroenterol 2018; 53: 243-251
• 33 Tsuchiya I, Kato Y, Tanida E. et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: Prospective randomized controlled trial. Dig Endosc 2017; 29: 576-583
• 34 Maruoka D, Arai M, Kasamatsu S. et al. Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: A propensity score-matching analysis. Dig Endosc 2017; 29: 57-64
• 35 Yamasaki A, Yoshio T, Muramatsu Y. et al. Vonoprazan is superior to rabeprazole for healing endoscopic submucosal dissection: Induced ulcers. Digestion 2018; 97: 170-176
• 36 Hirai A, Takeuchi T, Takahashi Y. et al. Comparison of the effects of vonoprazan and lansoprazole for treating endoscopic submucosal dissection-induced artificial ulcers. Dig Dis Sci 2018; 63: 974-981
• 37 Ishii Y, Yamada H, Sato T. et al. Effects of vonoprazan compared with esomeprazole on the healing of artificial postendoscopic submucosal dissection ulcers: A prospective, multicenter, two-arm, randomized controlled trial. Gastroenterol Res Pract 2018; 2018: 1615092
• 38 Jaruvongvanich V, Poonsombudlert K, Ungprasert P. Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018; 30: 1416-1421
• 39 Mochizuki S, Uedo N, Oda I. et al. Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial): a multicentre prospective randomised controlled non-inferiority trial. Gut 2015; 64: 397-405